Molecular data
| Molecular formula | Tesamorelin: C221H366N72O67S; Ipamorelin: C38H49N9O5 |
|---|---|
| Molecular weight | 5135.8 Da |
| Sequence | Tesamorelin: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu (trans-3-hexenoyl modified at N-terminus); Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Sequence length | 44 residues |
| CAS / identifier | Tesamorelin CAS 218949-48-5; Ipamorelin CAS 170851-70-4 |
| Physical form | Lyophilized powder |
| Available sizes | 14mg |
How it works
GHRH Receptor Agonism
Tesamorelin is a synthetic, stabilized analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth-hormone secretion while preserving the body's normal pulsatile GH release pattern — unlike exogenous GH administration.
- Selective GHRH-receptor agonism at the pituitary
- Preserves physiological pulsatile GH secretion
- Stimulates downstream IGF-1 production
Selective GHS-R Agonism
Ipamorelin is a pentapeptide growth-hormone secretagogue that acts on the ghrelin receptor (GHS-R1a). It is noted as the first highly selective GHS — research shows it stimulates GH release without significantly raising ACTH, cortisol, or prolactin.
- Acts on the ghrelin receptor (GHS-R1a), a GHRP-like pathway
- Highly selective for GH release among secretagogues
- Minimal effect on cortisol, prolactin, ACTH in research models
Combined GH-Axis Stimulation
Pairing a GHRH analog with a ghrelin-receptor secretagogue engages two distinct pituitary pathways. Research into GHRH + GHRP combinations examines whether the two mechanisms act in a complementary fashion on growth-hormone release.
- Targets GHRH-R and GHS-R simultaneously
- Studied as a complementary, two-pathway research model
- Both components act on endogenous GH secretion, not exogenous GH
What the research shows
GH / IGF-1 Axis Research
Both components are studied as tools for examining endogenous growth-hormone secretion and downstream IGF-1 signaling without exogenous GH.
Ishida et al. 2020
GHRH-R + GHS-R Signaling
Ipamorelin was characterized as the first selective GHS; pharmacological profiling confirmed it acts via a GHRP-like (ghrelin) receptor.
Raun et al. 1998
Body Composition Models
Tesamorelin's Phase III research demonstrated GH-mediated reductions in visceral adipose tissue, making it a reference GHRH-analog research model.
Falutz et al. 2010
Bone Mineral Content
In adult female rats, the GH secretagogues ipamorelin and GHRP-6 were shown to increase bone mineral content as measured by DXA.
Svensson et al. 2000
Specification
| Product Type | Two-peptide research blend |
|---|---|
| Component 1 | Tesamorelin 12 mg — GHRH(1-44) analog |
| Component 2 | Ipamorelin 2 mg — GHS pentapeptide |
| Tesamorelin Molecular Weight | 5135.8 Da |
| Ipamorelin Molecular Weight | 711.86 g/mol |
| Total Peptide Content | 14 mg per vial |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage (lyophilized) | -20°C for long-term stability |
| Storage (reconstituted) | 2–8°C, use within 14 days |
| COA | Included with every order |
Frequently asked questions
What is the TESA / IPA blend?
TESA / IPA is a two-peptide research blend combining Tesamorelin (12 mg) — a stabilized analog of growth-hormone-releasing hormone — with Ipamorelin (2 mg), a selective growth-hormone secretagogue that acts on the ghrelin receptor. The two compounds engage different pituitary pathways involved in growth-hormone release.
How do Tesamorelin and Ipamorelin work differently?
Tesamorelin activates the GHRH receptor, mimicking the body's own growth-hormone-releasing hormone. Ipamorelin activates the ghrelin receptor (GHS-R1a), a separate GHRP-like pathway. Both ultimately stimulate endogenous GH secretion, but through distinct receptors — which is the rationale for studying them together.
Why are a GHRH analog and a GHRP combined?
GHRH analogs and growth-hormone-releasing peptides act on two different receptors in the pituitary. Research into combinations examines whether engaging both pathways produces a complementary effect on growth-hormone release compared with either mechanism alone.
Is Ipamorelin selective?
Yes — Ipamorelin was described in the foundational 1998 research as the first selective growth-hormone secretagogue. Studies show it stimulates GH release without significantly increasing ACTH, cortisol, prolactin, or other pituitary hormones, even at doses well above the effective dose for GH release.
Is this blend FDA approved?
Tesamorelin is FDA-approved as a pharmaceutical (Egrifta) for a specific clinical indication. Ipamorelin is not approved for human use, and this specific TESA / IPA blend is not an approved product. It is supplied strictly for in vitro laboratory research and is not for human or veterinary use.
How should the TESA / IPA blend be stored?
Lyophilized blend should be stored at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, it should be kept at 2–8°C and used within approximately 14 days to preserve the integrity of both peptides.
Literature
- PUBMED Ipamorelin, the First Selective Growth Hormone Secretagogue
- PUBMED The GH Secretagogues Ipamorelin and GH-Releasing Peptide-6 Increase Bone Mineral Content in Adult Female Rats
- PUBMED Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation
- JOURNAL Growth Hormone Secretagogues: History, Mechanism of Action, and Clinical Development
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.